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Human ﬁlamins are large actin-crosslinking proteins com-
posed of an N-terminal actin-binding domain followed by
24 Ig-like domains (IgFLNs), which interact with numer-
ous transmembrane receptors and cytosolic signaling pro-
teins. Here we report the 2.5A ˚ resolution structure of a
three-domain fragment of human ﬁlamin A (IgFLNa19–
21). The structure reveals an unexpected domain arrange-
ment, with IgFLNa20 partially unfolded bringing IgFLNa21
into close proximity to IgFLNa19. Notably the N-terminus
of IgFLNa20 forms a b-strand that associates with the CD
face of IgFLNa21 and occupies the binding site for integrin
adhesion receptors. Disruption of this IgFLNa20–IgFLNa21
interaction enhances ﬁlamin binding to integrin b-tails.
Structural and functional analysis of other IgFLN domains
suggests that auto-inhibition by adjacent IgFLN domains
may be a general mechanism controlling ﬁlamin–ligand
interactions. This can explain the increased integrin bind-
ing of ﬁlamin splice variants and provides a mechanism by
which ligand binding might impact ﬁlamin structure.
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Introduction
By crosslinking actin ﬁlaments and interacting with trans-
membrane receptors and cytosolic signaling proteins, ﬁla-
mins play important roles in regulating the dynamics of the
actin cytoskeleton and integrating cellular mechanics and
signaling (Stossel et al, 2001).
Vertebrate ﬁlamins are non-covalent dimers of 240–
280kDa subunits composed of an N-terminal actin-binding
domain formed from two calponin homology domains fol-
lowed by a rod region composed of 24 tandem immuno-
globulin-like domains (IgFLN1–24) (Gorlin et al, 1990;
Stossel et al, 2001; van der Flier and Sonnenberg, 2001).
Dimerization is mediated via the C-terminal IgFLN24 (Pudas
et al, 2005). Flexible hinges between IgFLN15 and 16 and
IgFLN23 and 24 result in a V-shaped ﬂexible actin crosslinker
capable of stabilizing orthogonal networks with high-angle
F-actin branching (Hartwig et al, 1980). In addition to
crosslinking F-actin, ﬁlamins act as scaffolds for a growing
list of transmembrane receptors, signaling and adapter
proteins (Stossel et al, 2001; Feng and Walsh, 2004;
Popowicz et al, 2006). In general, these interactions are
mediated by the C-terminal domains, IgFLN 16–24, enabling
ﬁlamin to complex multiple partners in close proximity to
one another, potentially enhancing signal transduction (Ohta
et al, 2006).
Humans and mice each have three homologous ﬁlamin
genes encoding the proteins ﬁlamin A, B and C; of these,
ﬁlamin A (FLNa) is the most abundant and widely expressed
(Stossel et al, 2001; van der Flier and Sonnenberg, 2001). In
mice, FLNa expression is essential for proper cardiac and
vascular development (Feng et al, 2006; Hart et al, 2006),
FLNb is required for skeletal and microvascular development
(Zhou et al, 2007) and FLNc is necessary for normal myogen-
esis (Dalkilic et al, 2006). In humans, heterozygous null FLNa
alleles result in defective neuronal migration causing peri-
ventricular heterotopia (Fox et al, 1998), while certain FLNa
missense mutations cause familial cardiac valvular dystrophy
(Kyndt et al, 2007) and putative gain-of-function mutations
result in a spectrum of congenital malformations generally
characterized by skeletal dysplasias (Robertson et al, 2003).
Mutations in FLNb cause a class of diseases with abnormal
vertebral segmentation, joint formation and skeletogenesis
(Krakow et al, 2004) and an FLNc mutation causes an
autosomal dominant myoﬁbrillar myopathy (Vorgerd et al,
2005). The diversity in phenotypes associated with different
ﬁlamin mutations reveals that ﬁlamins perform a variety of
essential functions and the current evidence suggests that in
many cases speciﬁc disease phenotypes will result from
disruption of speciﬁc interactions between IgFLN domains
and their binding partners.
Despite identiﬁcation of more than 39 vertebrate ﬁlamin-
binding proteins (Stossel et al, 2001; Popowicz et al, 2006),
relatively little is known about how binding is regulated, how
the IgFLN domains are arranged with respect to one another
or how the arrangement of IgFLN domains modulates the
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3993ligand-binding activity of adjacent domains. We previously
identiﬁed IgFLNa21 as the major binding site in FLNa for
integrin adhesion receptors (Kiema et al, 2006). Integrins,
ab-heterodimers that span the plasma membrane, connect
the extracellular environment to the actin cytoskeleton
(Hynes, 2002). Thus, ﬁlamin–integrin complexes could pro-
vide a mechanical and biochemical link through which the
dynamic actin cytoskeleton could respond to external cues.
Indeed, modulation of integrin–ﬁlamin binding through both
gain-of-function and loss-of-function mutations in integrin
b-tails modulates cell migration (Calderwood et al, 2001)
and alternative splicing of ﬁlamin genes, which results in
deletions of portions of the rod domain, enhances integrin
binding and affects myogenesis (Xie et al, 1998; Xu et al,
1998; van der Flier et al, 2002).
The structure of IgFLNa21 in complex with a b7 integrin
peptide conﬁrmed that IgFLNa21 is a b-sandwich composed
of two b-sheets, similar to other human and Dictyostelium
discoideum IgFLNs (Fucini et al, 1997; McCoy et al, 1999;
Popowicz et al, 2004; Kiema et al, 2006; Nakamura et al,
2006). The integrin b7 peptide binds to the CD face of the
IgFLNa21 b-sandwich and this may represent a general
mechanism for IgFLN domain–ligand interactions as other
IgFLNs also bind their respective ligands at the CD face
(Kiema et al, 2006). Integrin binding to IgFLNa21 can be
inhibited by phosphorylation of the integrin tail or by other
integrin tail binding proteins that compete with ﬁlamin
(Kiema et al, 2006); however, whether ﬁlamin’s ligand-
binding activity is itself regulated remained unclear. To date,
the only reported multi-domain structures of ﬁlamin are of
two- and three-domain fragments of D. discoideum ﬁlamin
(ddFLN), where the domains form an elongated zigzag chain
(McCoy et al, 1999; Popowicz et al, 2004). ddFLN is different
from vertebrate ﬁlamins in that it contains only six IgFLN
domains and dimerizes in an end-on antiparallel fashion
rather than the proposed parallel or v-shaped arrangement
for human ﬁlamins. To determine how adjacent human
ﬁlamin domains are oriented, we investigated an integrin-
binding three-domain fragment of FLNa, IgFLNa19–21. X-ray
crystallography shows that within this three-domain protein,
IgFLNa21 and IgFLNa19 are very similar to one another and
to other IgFLNs, whereas IgFLNa20 is partially unfolded
and its ﬁrst strand binds the integrin-binding CD face of
IgFLNa21. NMR and biochemical analyses indicate that the
IgFLNa20–21 domain pair inhibits integrin b-tail binding and
mutations perturbing the IgFLNa20–21 interaction enhance
integrin binding. Analysis of other domain pairs suggests that
this may be a general feature of ﬁlamin–ligand interactions.
Results
Crystal structure of IgFLNa19–21 reveals unexpected
domain arrangement
To study the domain arrangement of the major integrin-
binding site within ﬁlamin, we crystallized a fragment con-
taining human FLNa domains 19–21 (IgFLNa19–21).
Diffraction data to 2.5A ˚ resolution were used for the crystal-
lographic calculations (Table I). The asymmetric unit of the
crystal contained two molecules; accordingly, two copies of
partial poly-Ala models for IgFLNa21 and IgFLNa19 were
initially positioned in the asymmetric unit by the molecular
replacement program Phaser (Storoni et al, 2004). In the ﬁnal
model, both copies of IgFLNa19 and IgFLNa21 could be
completely built, but loops BC and DG of IgFLNa20 in
chain A and 56 residues in chain B could not be included
because of missing electron density (Figure 1A and B). The
ﬁnal R-factor values for the model remained moderate
(R¼25.3%, Rfree¼29.8%) apparently because of disorder
in the crystals resulting in missing electron density and
high B-factor values, especially in IgFLNa20 (Figure 1B).
Despite the disorder in IgFLNa20, its partial model could be
validated by locating anomalous selenium signals in their
appropriate positions of IgFLNa20 in chain A in crystals
grown from SeMet-labeled protein (Supplementary Figure
S1). As chain A is better resolved, and since non-crystal-
lographic symmetry restraints were used in the reﬁnement
(Supplementary data), the structure of chain Awas used in all
further analyses.
The domain arrangement of the IgFLNa19–21 fragment is
unexpected and different from other immunoglobulin-like
domain structures determined thus far (Figure 1A). The
three domains form an elongated shape but the domain
order along the long axis of the fragment is not sequential.
Instead, IgFLNa19 is followed by IgFLNa21 and then
IgFLNa20. The b-strands of IgFLNa19 and IgFLNa21 are
arranged roughly along the long axis of the fragment,
whereas the main part of IgFLNa20 is located across the
loops of IgFLNa21 roughly perpendicular to the long axis.
While the N-terminus of the fragment is at one end, the
C-terminus is in the middle. This arrangement is only possible
because IgFLNa20 does not have a complete immunoglobu-
lin-like fold and interacts with IgFLNa21 in an unusual way.
The ﬁrst part of IgFLNa20 is separated from the rest of
IgFLNa20 and, as discussed in more detail later, forms an
additional b-strand next to the CFG b-sheet of IgFLNa21
Table I Crystallographic statistics of IgFLNa19–21 (2J3S)
Data collection
Space group C2221
Cell dimensions
a, b, c (A ˚) 72.3, 78.4, 229
a, b, g (deg) 90
Resolution (A ˚) 43.4–2.50 (2.56–2.50)
a
Rsym 7.3 (26.7)
I/sI 17.3 (3.95)
Completeness (%) 98.7 (89.9)
Redundancy 6.59 (3.30)
Reﬁnement
Resolution (A ˚) 43.4–2.50
No. of reﬂections 20422
Rwork/Rfree (%) 25.3/29.8
No. of atoms
Protein 3724
Ligand/ion 32
Water 23
Average B-factors (A ˚ 2)
Protein 33.6 [42.8]
b
Ligand/ion 55.9
Water 24.2
R.m.s. deviations
Bond lengths (A ˚) 0.016
Bond angles (deg) 1.45
aHighest resolution shell is shown in parentheses.
bThe values in brackets are calculated including the TLS tensor
contribution with the program tlsanl.
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of IgFLNa21, interacting mainly with the BC loop of
IgFLNa21. As a consequence of b-strand A being separated,
the half of the IgFLNa20 immunoglobulin sandwich that
should include b-strands ABED, as seen in IgFLNa19 and
IgFLNa21 (Figure 1D), is rather distorted in IgFLNa20
(Figure 1C).
While IgFLNa20 has an unusual fold, IgFLNa19 and
IgFLNa21 are very similar to one another (Figure 1C) and to
previously published IgFLN structures (Fucini et al, 1997;
McCoy et al, 1999; Popowicz et al, 2004; Pudas et al, 2005;
Kiema et al, 2006; Nakamura et al, 2006). IgFLNa19 and
IgFLNa21 can be superimposed with an r.m.s.d. of 1.50A ˚ for
89 Ca atoms, with the biggest differences observed in the BC
and DE loops (Figure 1D). We previously reported the struc-
ture of IgFLNa21 bound to a peptide from the integrin b7
cytoplasmic tail (PDB code 2BRQ) (Kiema et al, 2006), and
comparison of the two IgFLNa21 structures reveals good
alignment of the b-strands (r.m.s.d., 0.60A ˚ for 40 Ca
atoms) but BC and DE loops differ (overall r.m.s.d. 1.67A ˚
IgFLNa20
IgFLNa21
IgFLNa19
NB
CA
CB
NA
G
F
A
G F
C
D
BC
Loop
C
DE
Loop
NH2
COOH
A
B
C D
E
F
A'
AB
D C
Figure 1 Structure of IgFLNa19–21. (A) Ribbon diagram of the asymmetric unit of the crystals containing two molecules of IgFLNa19–21,
IgFLNa19 (yellow), IgFLNa20 (red) and IgFLNa21 (green). The N- and C-termini of molecules A and B are marked as well as b-strands G, Fand
C of IgFLNa21 in chain A. Scale bar in the bottom right, 25A ˚.( B) The same structure as in panel A, now colored according to the calculated
total atomic temperature factor (B-factor) values of Ca atoms. The range of B-factor values is from 11 to 143A
2; blue color indicates the lowest
values (11–49A ˚ 2), green and yellow higher values (50–79A ˚ 2) and orange and red the highest values (80–143A
2). (C) Ribbon diagram of the
isolated IgFLNa20 in the context of IgFLNa19–21. The three-stranded CFG b-sheet that is well ordered in the structure is labeled. Note that
b-strand D partially interacts with this sheet. The two disordered loops (BC and DE) absent from the model are arbitrarily indicated with dashed
lines. (D) Superimposition of IgFLNa19 (yellow) and IgFLNa21 (green) in the same orientation as panel C.
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attributed to the contacts with IgFLNa20 (loop BC) in the
three-domain structure and the presence of a covalently
bound glutathione molecule in 2BRQ (loop DE).
The crystallographic results showed an unexpected
domain arrangement of IgFLNa19–21. To test if the whole
arrangement of IgFLNa19–21 is stable without the various
interactions provided by crystal contacts, we performed a
molecular dynamics simulation of a single IgFLNa19–21. As
domain–domain movements usually occur on a nanosecond
scale (Haran et al, 1992; Wang et al, 2006), the extension of
the simulation to 10ns should be long enough to detect at
least the beginning of substantial domain movements.
However, during the simulation, further domain–domain
packing is observed that stabilize the IgFLNa19–21 structure
(Supplementary Figure S2). When compared to the position
of IgFLNa21, IgFLNa19 shows only slight movement, while
the removal of crystal contacts releases IgFLNa20 to move
closer to the head of IgFLNa21 (Supplementary Figure S2).
Overall, the simulation results suggest that the domain
arrangement of IgFLNa19–21 is rather stable as seen in the
crystal.
IgFLNa20 binds the integrin-binding surface of IgFLNa21
We have previously shown that integrin b-tails bind to the CD
face of IgFLNs, with the integrin tail forming a b-strand that
extends the b-sheet formed by the CFG strands (Kiema et al,
2006). In the current structure, the ﬁrst strand of IgFLNa20
extends the IgFLNa21 CFG b-sheet in a manner analogous to
the integrin peptide and completely covers the integrin-bind-
ing site (Figure 2). Despite little primary sequence similarity
between the IgFLNa21-binding portions of the integrin b7 tail
BC loop
DE loop
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C D
IIe786
Thr784
IIe782
Ser780
Tyr778
Phe2285
Leu2283
Arg2148
Arg2146
IIe2144
Glu2142
Val2140
Phe2285
Leu2283
PLYKSA I TTTINP
PIYKSAVTTVVNP
GRVKES I TRRRRA
Integrin β7
Integrin β1A
IgFLNa20
Figure 2 Comparison of interaction of IgFLNa21 with IgFLNa20 and integrin b7. (A) Superimposition of the ribbon diagram of the interaction
between the CD face of IgFLNa21 (green) and the ﬁrst part of IgFLNa20 (red) with the published complex (2BRQ) between IgFLNa21 (purple)
and the integrin b7 cytoplasmic domain (gold). The BC and DE loops that differ between the two IgFLNa21 structures are indicated. (B, C)
Electron density corresponding to the ﬁrst strand of IgFLNa20, shown as difference (omit) map calculated without the residues 2136–2159
(shown in purple in panel C). The map is shown as a blue mesh at 2.5s. The side chains pointing toward b-strand D of IgFLNa21 are well
visible in the electron density. (D) Similar superimposition as in panel Awith the peptides and IgFLNa21 strand C and D shown as stick models.
Colors as in panel A. (E, F) Details of interaction between IgFLNa21 (purple in panel E, green in panel F) and the integrin b7 peptide (E: yellow)
and IgFLNa20 (F: red). In both cases, hydrogen bonds are shown as dashed lines. (G) Sequence alignment shows that the IgFLNa20 sequence
has little similarity to integrin sequences. Notably the most conserved residues Lys (2141 in IgFLNa20) and Thr (2145) point out from the
interaction surface.
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adopt very similar structures (Figure 2D–F) (r.m.s.d. 0.74A ˚
for nine Ca atoms) and bury comparable areas (727A
2 for
IgFLNa20 and 667A
2 for b7) of accessible surface on the
CD face of IgFLNa21. As was observed for the b7 integrin–
IgFLNa21 complex, the ﬁrst strand of IgFLNa20 forms hydro-
gen bonds to strand C of IgFLNa21 (Figure 2D and F). We
have predicted that the speciﬁcity of this kind of IgFLN–
ligand interaction is mainly determined by the hydrophobic
interactions between the binding partner and the side chains
of IgFLN b-strand D side chains (Kiema et al, 2006). The
common hydrophopic interaction shared between integrin b7
tail and IgFLNa20 is Ile (IgFLNa residue 2144 and b7 residue
782) that is sandwiched between Leu2283 and Phe2285 of
IgFLNa21 b-strand D (Figure 2D–F). Other interactions of
IgFLNa20 seem to be less optimal than those of the integrin
tail. In particular, the four Arg residues (2146–2149) of
IgFLNa20 appear to form suboptimal interactions and are
quite uncommon for a b-strand (Figure 2F).
As described above, molecular dynamic simulations pre-
dict that the interaction between the ﬁrst part of IgFLNa20
and the CD face of IgFLNa21 is stable, but to test this in
solution NMR experiments were performed. The interaction
between IgFLNa21 and IgFLNa20 was validated by solution-
state NMR in two ways: (i) Addition of IgFLNa20 to
15N-
labeled IgFLNa21 gave selective shifts concentrated on the CD
face of IgFLNa21 (Figure 3A). This pattern is very similar to
that observed with the b7 integrin (Kiema et al, 2006) and
conﬁrms that the CD face of IgFLNa21 is involved in the
binding of IgFLNa20. Furthermore, the shifts induced by a
truncated IgFLNa20 protein (residues 2167–2235), which
lacks the residues forming the ﬁrst b-strand, were very
much reduced (Figure 3A), demonstrating that this region
of IgFLNa20 is required for binding IgFLNa21. (ii) Since
there is only one Ala–Leu pair in the IgFLNa19–21 sequence
(Ala2272 and Leu2271), selective labeling (1-
13C-Leu,
15N-
Ala) of IgFLNa19–21 allowed Ala2272 in strand C to be
uniquely identiﬁed in the complicated spectrum of the
triple domain; this resonance was observed to be consi-
derably shifted in IgFLNa19–21 at 371C( dHN¼8.080p.p.m.,
dN¼124.918p.p.m.) compared to that in IgFLNa21 alone
(dHN¼8.921p.p.m. and dN¼124.970p.p.m.). Taken together,
these NMR experiments give strong support to the interaction
of the N-terminus of IgFLNa20 with the CD face of IgFLNa21
as seen in the crystal structure.
IgFLNa20 inhibits integrin binding to IgFLNa21
IgFLNa20 and integrin b-tails bind to the same site on
IgFLNa21 (Figure 2), suggesting that they may compete for
binding to IgFLNa21. NMR analysis indicates that when free
in solution integrin b7 tails bind IgFLNa21 with a higher
afﬁnity than IgFLNa20 does, and that b7 tails can displace
free IgFLNa20 from IgFLNa21—evidenced by induction
of a new pattern of shifts following addition of b7 tails
(Supplementary Figure S3). However, in intact ﬁlamin,
IgFLNa20 is tethered to IgFLNa21, thus increasing the effec-
tive local concentration and the occupancy of the interaction.
To assess the impact of IgFLNa20 on integrin binding to
IgFLNa21, we compared the binding of GST-IgFLNa21 and
the two domain fragment GST-IgFLNa20–21. GST-IgFLNa21
bound to recombinant b7 integrin tails in a dose-dependent
manner (Figure 3B). When quantiﬁed by scanning densito-
metry, curve ﬁtting analysis indicated an apparent Kd
of 0.770.1mM, in good agreement with our previous data
(Kiema et al, 2006). Notably, binding of the two-domain
fragment to b7 was much lower (Figure 3B). A reliable
calculation of the binding afﬁnity for this interaction was
not possible because saturation of GST-IgFLNa20–21 binding
to b7 could not be achieved.
Structural analyses show that the ﬁrst strand of IgFLNa20
is responsible for the interaction with IgFLNa21. We therefore
generated a truncated IgFLNa20–21 protein (residues 2152–
2329) lacking the ﬁrst 13 amino acids of IgFLNa20, which
normally form the interacting strand. This protein displayed a
signiﬁcant increase in b7 binding compared to wild-type
IgFLNa20–21 (Figure 4A). To speciﬁcally disrupt the ﬁrst
strand interaction with IgFLNa21 without deleting a large
stretch of amino acids, we substituted Ile2144 with Glu.
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Figure 3 IgFLNa20–21 domain pair inhibits integrin binding.
(A) Chemical shift perturbations of resonances in the U-
15N-IgFLNa21
domain induced by a 30-fold excess of IgFLNa20 (dark gray) or
IgFLNa20 var-1 (light gray). The combined chemical shifts of amide
proton and nitrogen resonances in [
1H,
15N]-HSQC spectra were
calculated using the formula DdHN,N¼[(DdHN)
2þ(0.154 DdN)
2]
1
2.
The black lines correspond to residues whose resonances were
severely broadened on addition of IgFLNa20. (B) Binding of puriﬁed
GST-IgFLNa21 or GST-IgFLNa20–21 to b7 integrin tails was assessed
by protein staining of pull-down assays. Protein binding was
quantiﬁed by densitometry and ﬁlamin bound was calculated as
the ratio of ﬁlamin bound to ﬁlamin in the loading control in each
experiment (mean7s.e.; nX3).
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tail (Figure 2E–G), which is important for b7 integrin binding
to ﬁlamin (Calderwood et al, 2001), and occupies a hydro-
phobic pocket on IgFLNa21 that is important for integrin
binding (Kiema et al, 2006). We predicted that the introduc-
tion of a large charged residue at this site should destabilize
the interaction, and observed that IgFLNa20–21 (I2144E), like
the N-terminal truncation, displayed enhanced b7 integrin
binding in comparison to wild-type IgFLNa20–21 (Figure 4A).
Thus, disruption of the IgFLNa20–IgFLNa21 interaction can
enhance integrin binding, presumably through exposure of
the integrin binding CD face on IgFLNa21.
IgFLNa20 inhibits integrin binding to intact ﬁlamin
The experiments described above were performed using
short, bacterially expressed recombinant fragments of ﬁla-
min. To verify the results in the context of ﬁlamin expressed
in cultured cells, we compared the ability of integrin b-tails to
pull down wild-type and mutated ﬁlamin from cell lysates.
FLNa lacking IgFLNa20 (FLNaD20) exhibited enhanced bind-
ing to b7 integrin tails (Figure 5A), consistent with an
inhibitory role for IgFLNa20. Similar results were obtained
using both untagged and GFP-tagged FLNa (Figure 5B); this
effect was not limited to b7 integrins, as removal of IgFLNa20
also enhanced binding to b1A tails (Figure 5B), consistent
with the general ability of b-integrin tails to bind to the CD
face of IgFLNa21 (Kiema et al, 2006).
The binding of FLNa (I2144E), containing the point muta-
tion that destabilizes the IgFLNa20–IgFLNa21 interaction,
was also assessed (Figure 5C). GFP-FLNa (I2144E) displayed
enhanced binding to b7 and b1A integrin tails in pull-down
assays from cell lysates (Figure 5C). Thus in the context of
full-length ﬁlamin, IgFLNa20 masks the major integrin-bind-
ing site in IgFLNa21 and a single point mutation is sufﬁcient
to expose the integrin-binding site and enhance integrin–
ﬁlamin interactions.
Filamin splice variants lack the inhibitory IgFLNa20
sequence
The observation that an intramolecular interaction between
two adjacent IgFLNa domains reduces integrin binding to
ﬁlamin suggests that this interaction may form part of a
regulatory mechanism controlling ﬁlamin association with
ligands. van der Flier et al (2002) have shown that naturally
occurring FLNa and FLNb splice variants (var-1) exhibit
enhanced binding to a variety of integrin b-tails. These splice
variants lack a 41-amino-acid sequence encompassing the
C-terminal part of IgFLNa19 and the N-terminal part of
IgFLNa20, including the ﬁrst strand of IgFLNa20. We have
conﬁrmed the previously reported increase in b1A integrin-
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Figure 4 Mutations in the ﬁrst strand of IgFLNa20 relieve inhibition of integrin binding. Binding of puriﬁed GST-IgFLNa21, -IgFLNa20–21, -
IgFLNa20–21(2152–2329) or -IgFLNa20–21 I2144E (A) or GST-IgFLNa19 or -IgFLNa18–19 (B)t ob7 integrin tails was assessed by protein
staining of pull-down assays. Protein binding was quantiﬁed by densitometry and calculated as described in Figure 3 (mean7s.e.; nX3).
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FLNa19–21 var-1 expressed in cultured cells and shown that
binding to b7 tails is also increased (Figure 6A). We have also
shown increased binding of puriﬁed bacterially expressed
GST-FLNa19–21 var-1 protein to both b7 and b1A integrin
tails (Figure 6B). Alternative splicing may therefore be one
mechanism by which the inhibitory intramolecular
IgFLNa20–IgFLNa21 interaction is regulated to control ﬁlamin’s
ligand-binding activities.
Auto-inhibition of ligand binding by other
even-numbered domains
The preceding data indicate that IgFLNa20 negatively regu-
lates ligand binding to IgFLNa21. Structural analysis of
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similar (Figure 1D), and mutagenesis and NMR analysis
suggest that IgFLNa19 and IgFLNa21 both bind integrin
b-tails in a very similar fashion (Kiema et al, 2006). We
therefore tested whether IgFLNa18 could negatively regulate
integrin binding to IgFLNa19. GST-IgFLNa19 bound b-integ-
rins in a dose-dependent manner similar to IgFLNa21, but
in comparison the two-domain construct GST-IgFLNa18–19
displayed severely reduced binding (Figure 4B). Thus, the
auto-inhibition of ligand binding to IgFLN domains by the
preceding even-numbered IgFLNa domains may be a more
general phenomenon.
Discussion
We have described the molecular structure of a three-domain
fragment of human FLNa. This reveals an unexpected
arrangement with domains in a non-sequential order contrary
to previous proposed models, and this arrangement is possi-
ble because IgFLNa20 adopts an unusual structure. The
structure also reveals a mechanism of auto-inhibition, limit-
ing accessibility to the integrin-binding site in ﬁlamin. This
auto-inhibitory mechanism may be extended to other ligand-
binding sites in ﬁlamin. Finally, loss of auto-inhibition in
ﬁlamin splice variants provides a molecular explanation for
their enhanced integrin-binding activity.
Structure of IgFLNa19–21
Vertebrate ﬁlamins contain 24 tandem immunoglobulin-like
domains. Until now, our understanding of how adjacent
IgFLN domains interact has been based on the structures of
two- and three-domain fragments of ddFLN, where the
domains form an elongated zigzag chain (Figure 7A)
(McCoy et al, 1999; Popowicz et al, 2004). The structure of
IgFLNa19–21 described here introduces another model for
IgFLN packing (Figure 7B). In this structure, IgFLNa20 and
IgFLNa21 fold together because IgFLNa20 is divided into two
parts: the ﬁrst part forms a b-strand next to strand C of
IgFLNa21, and the rest lies on top of the BC loop of IgFLNa21.
IgFLNa20 therefore forms an incomplete Ig-like fold. The
usual arrangement of multiple Ig-like domains is an extended
linear arrangement, for example that found in ddFLN
(Popowicz et al, 2004), ﬁbronectin (Leahy et al, 1996) or
titin (Marino et al, 2005). Domain swapping (Rousseau et al,
2003) and interactions between non-contiguous domains
(Pickford et al, 2001) have been observed previously but
this is the ﬁrst interdomain interaction of this type we are
aware of.
Using NMR techniques we tested whether the pairing
between IgFLNa20 and IgFLNa21 also takes place in solution
and showed that the interaction of the ﬁrst part of IgFLNa20
and the CD face of IgFLNa21 took place between isolated
domains, and also in the context of the three-domain
IgFLNa19–21 fragment. Thus, we believe that this arrange-
ment represents a genuine property of this ﬁlamin fragment.
Gorlin et al (1990) ﬁrst reported the predicted amino-acid
sequence of human ﬁlamin, and, noting that the N-terminal
parts of some of the more C-terminal even-numbered do-
mains (IgFLNa16, 18, 20 and 22) are different from other
ﬁlamin domains (Supplementary Figure S4), proposed that
these differences may change the way in which neighboring
domains interact (Gorlin et al, 1990). We have now shown
that the N-terminal portion of IgFLNa20 is involved in
a domain–domain interaction that results in inhibition of
ligand binding to IgFLNa21. Whether other similar structural
and functional domain pairs exist in ﬁlamins remains to be
determined; however, we have observed that IgFLNa18 in-
hibits integrin binding to IgFLNa19. Furthermore, recent
NMR structures of individual IgFLNc16 (PDB code 2D7N),
IgFLNb18 (2DMC) and IgFLNb20 (2DLG) domains are very
similar to the structure of IgFLNa20 in our crystal; they all
lack the ﬁrst b-strand and the remaining BEG sheet is
characteristically tilted when compared to complete IgFLNs.
This may suggest that IgFLN16 and IgFLN17, and IgFLN18
and IgFLN19 also form domain pairs, possibly resulting in
inhibition of ligand binding to the odd-numbered domains.
Interestingly, the NMR structure of IgFLNb22 (2D7P) has all
the b-strands in appropriate positions. Currently, we have no
evidence for domain pairs in IgFLN1–15.
Considering that the chain of IgFLNs continues in both
directions from the IgFLNa20–21 domain pair, it is interesting
that the N- and C-termini of the domain pair are only about
20A ˚ apart, whereas in an arrangement as in the ddFLN, this
120 A
N C
45 6
N
C
19 21 20
N C
19 21 20 18
N
C
19 20 21 18
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80 A
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D
Figure 7 Illustration of ﬁlamin domain arrangements. (A) ddFLN
Ig domain 4–6. (B) Human IgFLNa19–21. (C) A hypothetical model
of two ﬁlamin domain pairs showing that in this kind of arrange-
ment the N- and C-termini of the four-domain fragment would be
close to each other. Additional IgFLN domains or domain pairs can
be accommodated in this model by allowing ﬂexibility in the
interdomain linker regions. (D) A hypothetical model showing
how binding of an integrin b-tail (arrow) to IgFLNa21 might affect
the overall arrangement of IgFLNa18–21. Our data do not indicate
whether ligand binding to one domain pair impacts adjacent
domain pairs.
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domain pairs should reduce the overall length of the ﬁlamin
rod region. If additional IgFLN domain pairs can form simul-
taneously, more signiﬁcant effects on rod length are expected
(Figure 7C). Because published EM images of ﬁlamin lack
sufﬁcient resolution to clearly identify individual domains
and show considerable conformational heterogeneity in the
rod (Tyler et al, 1980; Castellani et al, 1981; Hartwig and
Stossel, 1981), it is difﬁcult to reliably relate our ﬁndings to
EM images. However, Gorlin et al (1990) report that while
IgFLNa1–15 has a contour length of B55nm, yielding an
average span of B3.7nm per IgFLNa, which is in good
agreement with that seen in ddFLN Ig domains (Popowicz
et al, 2004) (Figure 7A), IgFLNa16–23 only stretches over
B15nm (an average of B1.9nm per IgFLNa). This reveals a
difference in domain packing in the C-terminal portion of the
ﬁlamin rod, consistent with the localization of domain pairs
to this region.
Auto-inhibition of integrin binding by IgFLNa20
The N-terminal part of IgFLNa20 covered the integrin-binding
surface of IgFLNa21. In fact, IgFLNa20 interacted with
IgFLNa21 in a very similar way to the integrin b7 subunit
cytoplasmic tail (Kiema et al, 2006). Structural analysis
suggests that the intramolecular domain–domain interaction
is less optimal than the integrin binding: the integrin peptide
makes better hydrophopic interactions with IgFLNa21 than
IgFLNa20 does. In particular, Arg2146 and Arg2148 that are
located toward the end of the interacting b-strand of
IgFLNa20 appear to have rather unfavorable interactions
with IgFLNa21, although their side chains are well ordered
in our structure (Figure 2B and C). In accordance with this,
the presence of IgFLNa20 inhibited integrin binding to
IgFLNa21, but this inhibition was only partial. The auto-
inhibitory effect of IgFLNa20 was veriﬁed using deletion
and point mutants in the context of both ﬁlamin fragments
and full-length ﬁlamin.
Regulation of auto-inhibition of integrin binding
The discovery of intramolecular auto-inhibition of integrin
binding raises the possibility that this provides a mechanism
to regulate ﬁlamin–integrin interaction. If this is the case, the
cell must be able to release the auto-inhibition in certain
circumstances and so a mechanism for changing the con-
formation of the IgFLNa20–21 pair is required. Alternative
splicing of ﬁlamin mRNA provides one such mechanism.
Alternative splicing of FLNa has been shown to remove
exon 40, generating FLNa var-1 lacking 41 amino acids that
lie within IgFLNa19 and IgFLNa20 (van der Flier et al, 2002).
This results in loss of the auto-inhibitory ﬁrst b-strand of
IgFLNa20 and increased integrin binding. The corresponding
FLNb var-1 protein also exhibits enhanced integrin binding
(van der Flier et al, 2002), suggesting that IgFLNb20 plays a
similar auto-inhibitory role in modulating FLNb integrin
interactions. While the mRNA for these splice variants has
a weak but widespread distribution, factors regulating the
splicing remain unknown, so it is unclear under what condi-
tions splicing is used to release auto-inhibition of integrin
binding.
Other possible ways to regulate the auto-inhibition of
ﬁlamin’s integrin-binding site include phosphorylation and
mechanical force. Ser2152, a phosphorylation target for PKA,
PAK1 and RSK (Jay et al, 2000; Vadlamudi et al, 2002; Woo
et al, 2004), is located just after the ﬁrst strand of IgFLNa20.
In our structure, Ser2152 is exposed and susceptible to
phosphorylation. It has been suggested that phosphorylation
at this Ser may modulate integrin binding, but based on its
location, phosphorylation is unlikely to affect auto-inhibition
of integrin binding. Consistent with this, neither phospho-
mimicking nor phospho-blocking mutations at this site im-
pact integrin binding to an FLNa19–24 fragment (Travis et al,
2004). However, the effect that the negative charge intro-
duced by phosphorylation may have on other neighboring
domains remains to be tested.
In response to mechanical force transmitted through in-
tegrin adhesion receptors, FLNa is recruited to integrin-
mediated adhesion contacts where it has a mechanoprotec-
tive effect (Glogauer et al, 1998; D’Addario et al, 2002). It is
possible that mechanical forces acting on ﬁlamin alter the
conformation of the partially unfolded IgFLNa20, modulating
its auto-inhibitory effect and so controlling ﬁlamin integrin–
integrin interactions. Single molecule force spectroscopy has
shown that ddFLN domain 4 unfolds at lower forces than
other domains via a stable unfolded intermediate (Schwaiger
et al, 2004); similar studies on human ﬁlamin have shown
that human IgFLN domains have a broad range of unfolding
forces (Furuike et al, 2001). Stretching of ﬁlamin molecules
would potentially pull the ﬁrst strand of IgFLNa20 away from
IgFLNa21 exposing the CD face and enhancing binding of
ligands, including integrins, which could trigger signaling
cascades to respond to increased mechanical stress.
Effects of ligand binding on the overall arrangement
of ﬁlamin rod region
We have shown that IgFLNa20–21 is folded as a domain pair
and that integrin binding can outcompete the main interac-
tion between IgFLNa20 and IgFLNa21. As a consequence of
integrin binding, we would expect release of the ﬁrst part of
IgFLNa20 from its interaction with FLNa21. It will be im-
portant to determine the effect this has on the overall con-
formation of the IgFLNa20–21 after integrin binding. If
IgFLNa20 can form a complete immunoglobulin-like fold
after its ﬁrst strand is displaced from IgFLNa21, the overall
topology of the two-domain pair might change to resemble
the arrangement found in ddFLN (Figure 7D). This, in turn,
might change the overall length and orientation of the ﬁlamin
rod region. As noted above, the conformational heterogeneity
and limited resolution of EM images of ﬁlamin (van der Flier
and Sonnenberg, 2001) make it difﬁcult to relate them to
our atomic models. However, based on the domain packing
seen in ddFLN (Popowicz et al, 2004), the predicted length of
‘activated’ ﬁlamin monomers lacking any domain pairs
would be B100nm, in good agreement with 98710 nm
measurements by Castellani et al (1981) but longer than the
B80nm reported by Tyler et al (1980) and Hartwig and
Stossel (1981), which conceivably represents a form contain-
ing domain pairs. Thus, we envision that by inducing
changes in interdomain arrangements, integrin binding
might have long-range effect in ﬁlamin. Likewise, similar
effects are expected to be caused by ligand binding to other
ﬁlamin domain pairs.
Although further studies are required for a complete
molecular understanding of ﬁlamin topology and interac-
tions, our current structural and biochemical studies have
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that provide mechanisms for regulating ligand binding to
ﬁlamin and may allow ﬁlamin ligands to inﬂuence the length
and architecture of the ﬁlamin rod region.
Materials and methods
Protein production
Recombinant His-tagged integrin cytoplasmic tail model proteins
were produced and puriﬁed as previously described (Pfaff et al,
1998). IgFLNa19 (amino acids 2046–2141), IgFLNa21 (amino acids
2236–2329), IgFLNa20–21 (2142–2329), IgFLNa18–19 (amino acids
1955–2141), IgFLNa19–21 (amino acids 2046–2329) and IgFLNa19–
21 var-1 (amino acids 2046–2125 then 2168–2329) were generated
by polymerase chain reaction and subcloned into pGEX (Amer-
sham) or EGFP (BD Biosciences) vectors for expression of GST or
EGFP fusion proteins. Point mutations and deletions were
introduced by QuikChangeTM site-directed mutagenesis (Strata-
gene). All inserts were veriﬁed by DNA sequencing. GST fusion
proteins were produced in Escherichia coli BL21 cells and puriﬁed
on Glutathione Sepharose 4 Fast Flow medium (Amersham
Biosciences) according to the manufacturer’s instructions. The
IgFLNa19–21 fragment used for crystallization was cloned in
modiﬁed pET24d vector containing a His6 tag followed by tobacco
etch virus (TEV) cleavage site (Pudas et al, 2005). Protein was
produced in E. coli BL21(DE3) cells and puriﬁed on Ni-NTA Agarose
(Qiagen) according to the manufacturer’s instructions. The His6 tag
was cleaved with TEV protease (Invitrogen) during overnight
dialysis at 41C to 50mM NaCl and 50mM Tris–HCl pH 8.0.
Additional puriﬁcation was achieved by anion-exchange chromato-
graphy on Acell QMA matrix (Waters) and gel ﬁltration on HiLoad
16/60 Superdex 75 column (Amersham Biosciences).
Crystallography
The IgFLNa19–21 protein was crystallized using the hanging drop
vapor diffusion method at 221C by mixing 1ml of 30mg/ml protein
solution in 100mM NaCl, 50mM Tris and 1mM DTT pH 8.0 with an
equal volume of 1.6M (NH4)2SO4, 0.1M citric acid pH 6.1 and 10%
dioxane. The crystals were transferred to 0.25M KBr, 20% glycerol,
1.6M (NH4)2SO4 and 0.1M citric acid pH 6.1 before freezing under
liquid nitrogen. The data for ﬁnal structure solution were collected
at 100K at European Synchrotron Radiation Facility (Grenoble,
France) beam line ID23-1 by using MarMosaic 225 CCD detector
(Marresearch GmbH). The data were processed with the XDS
program package (Kabsch, 1993). Partial poly-Ala models for
IgFLNa19 and IgFLNa21 were derived from IgFLNc24 structure
(PDB code 1VO5) by replacing non-identical amino acids with Ala.
Two copies of each of the models were initially positioned by
molecular replacement program Phaser (Storoni et al, 2004) and the
ﬁnal model was generated by iterating between manual model
building with programs O (Jones et al, 1991) or Coot (Emsley and
Cowtan, 2004) and TLSþ restrained reﬁnement with Refmac 5.2
(Murshudov et al, 1997). Tight non-crystallographic symmetry
restrains between IgFLNa19 and IgFLNa21 of chains A and B were
used in the ﬁnal reﬁnement. Crystallographic images were
generated with PYMOL (DeLano Scientiﬁc, San Carlos, CA, USA;
http://www.pymol.org). Further details of the crystallographic
data, structure validation and molecular dynamics are given in
Supplementary data. Atomic coordinates and structure factors have
been deposited in the Protein Data Bank, accession code 2J3S.
NMR
IgFLNa20 (2141–2235) and IgFLNa20 var-1 (2167–2235) were
expressed from a pGEX-6P-2 vector with a Precission protease
cleavage site using BL21 codon plus cells (Stratagene) and uniform
labeling was achieved by growing in M9 minimal media with
15N-NH4Cl and
13C-glucose. Selective labeling of IgFLNa19–
21(1–
13C-L2271,
15N-A2272) was produced using a mixture of
labeled (1-
13C-leucine and
15N-alanine) and non-labeled amino
acids (0.1g for each per liter M9) (Peterson et al, 2001). The identity
and purity of the products were conﬁrmed by mass spectrometry
and SDS–PAGE. The b7-derived peptide
776PLYKSAITTTINP
788
(N-terminally acetylated and C-terminally amidated) was purchased
from EZBiolab (USA).
All NMR samples were buffered with 50mM sodium phosphate
(pH 6.10) containing 100mM NaCl and 5mM DTT in 90% H2O and
10% D2O. NMR data were collected at
1H frequencies of 500, 600
and 750MHz. The backbone amide
15N and
1H chemical shifts for
wild-type IgFLNa21 were assigned using a 1mM U-
13C,
15N-labeled
protein sample and standard triple resonance experiments (Astrof
et al, 1998). Gradient enhanced [
1H,
15N]-HSQC (Schleucher et al,
1994) experiments were used to carry out titrations for 100mM
IgFLNa21 with varying amounts of b7/IgFLNa20/IgFLNa20 var-1 at
251C. The [
1HN,
15N] chemical shifts for (1-
13C-L2271,
15N-A2272)-
IgFLNa19–21 were recorded with a 500mM sample at 371Co na
Bruker cryoprobe-equipped Avance 500MHz machine using a 3D
HNCO pulse sequence (Kay et al, 1994). NMR data processing was
carried out with NMRPipe (Delaglio et al, 1995) and SPARKY
(www.cgl.ucsf.edu/home/sparky). Spectra were referenced to the
water proton shift (4.766p.p.m. at 251C, 4.623p.p.m. at 371C)
(Wishart et al, 1995) with indirect referencing in the nitrogen
dimension using a
15N-
1H frequency ratio of 0.101329118 (IUPAC).
Binding assays and analysis
Binding assays using recombinant integrin tail model proteins were
performed as previously described (Pfaff et al, 1998; Calderwood
et al, 2001). For GFP fusion proteins, or full-length human FLNa or
FLNa mutants, Chinese hamster ovary (CHO) cells were transiently
transfected with 3mg of expression vector using LipofectamineTM
(Invitrogen), cells were harvested 24–48h later, lysed as described
previously (Calderwood et al, 2001) and binding assays were
performed. Anti-ﬁlamin mAb1680 (Chemicon) and anti-GFP (Rock-
land) antibodies were purchased.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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